Clinical effects of the CD13/CD33 ratio on the prognosis of myelodysplastic syndrome treated with azacitidine

Oka Satoko; Ono Kazuo; Nohgawa Masaharu

首页> 外文期刊>Leukemia and lymphoma >Clinical effects of the CD13/CD33 ratio on the prognosis of myelodysplastic syndrome treated with azacitidine

【24h】

Clinical effects of the CD13/CD33 ratio on the prognosis of myelodysplastic syndrome treated with azacitidine

机译：CD13 / CD33比率对氮酰硝基治疗髓细胞塑性综合征预后的临床疗效

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia and lymphoma》 |2020年第6期|共4页
作者
Oka Satoko; Ono Kazuo; Nohgawa Masaharu;
展开▼
作者单位

Japanese Red Cross Soc Wakayama Med Ctr Div Hematol Wakayama Japan;

Japanese Red Cross Soc Wakayama Med Ctr Div Pathol Wakayama Japan;

Japanese Red Cross Soc Wakayama Med Ctr Div Hematol Wakayama Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical effects of the CD13/CD33 ratio on the prognosis of myelodysplastic syndrome treated with azacitidine [J] . Oka Satoko, Ono Kazuo, Nohgawa Masaharu Leukemia and lymphoma . 2020,第5a6期

机译：CD13 / CD33比率对氮酰硝基治疗髓细胞塑性综合征预后的临床疗效
2. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine [J] . Dae Young Kim, Je Hwan Lee, Jung Hee Lee, Annals of hematology . 2010,第1期

机译：预测阿扎胞苷治疗骨髓增生异常综合征患者治疗反应和预后的各种标准的比较
3. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine [J] . Dae-Young Kim, Je-Hwan Lee, Jung-Hee Lee, Annals of Hematology . 2010,第1期

机译：预测阿扎胞苷治疗骨髓增生异常综合征患者反应和预后的各种标准的比较
4. Azanudeoside DNA Methyltransferase Inhibitor Drugs: Update on Clinical Applications in Myelodysplastic Syndromes and Acute Myeloid Leukemia [C] . Michael Lubbert, Michael Daskalakis, Philipp N. Ser, Weissenburg Symposium Biriciana . 2016

机译：硫代稳产苷DNA甲基转移酶抑制剂药物：更新骨髓增生综合征和急性髓性白血病的临床应用
5. Acute coronary syndromes: Predictors of clinical presentation and prognosis [D] . Kennon, Simon. 2002

机译：急性冠状动脉综合征：临床表现和预后的预测指标
6. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia [O] . Guillermo Garcia-Manero, Antonio Almeida, Aristoteles Giagounidis, 2016

机译：QUAZAR低风险MDS（AZA-MDS-003）试验的设计和原理：对IPSS低危型骨髓增生异常患者进行CC-486（口服阿扎胞苷）加最佳支持治疗与安慰剂加最佳支持治疗的随机3期研究依赖红细胞的贫血和血小板减少症引起的综合征和预后不良
7. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia [O] . Garcia-Manero, G, Almeida, A, Giagounidis, A, 2016

机译：QUAZAR低危MDS（AZA-MDS-003）试验的设计和原理：CCSS-486（口服阿扎胞苷）+最佳支持治疗与安慰剂+最佳支持治疗的IPSS低危骨髓增生异常患者的3期随机研究红细胞输血依赖性贫血和血小板减少症引起的综合征和预后不良

Clinical effects of the CD13/CD33 ratio on the prognosis of myelodysplastic syndrome treated with azacitidine

著录项

相似文献

相关主题

期刊订阅